A recent systematic review by Muller et al. that included 28 observational cohort studies of 298,717 patients revealed that the overall risk of cancer in IBD patients treated with anti-TNF was comparable to that of anti-TNF naïve [68]. The gene discussed is TNF; the disease is cancer.